What's the Optimal Lipids Level for Dialysis Patients? A Cohort Study from a Chinese Dialysis Center in a University Hospital

被引:6
作者
Yang, Wen-Ling [1 ]
Zhu, Xue-Yan [2 ]
Zhu, Ning [1 ]
Su, Chun-Yan [1 ]
Han, Qing-Feng [1 ]
Wang, Tao [1 ]
Zhang, Ai-Hua [1 ]
机构
[1] Peking Univ, Hosp 3, Dept Nephrol, Beijing, Peoples R China
[2] Jilin Med Univ, Dept Nephrol, Changchun, Jilin Province, Peoples R China
关键词
ATHEROSCLEROTIC CARDIOVASCULAR EVENTS; DENSITY-LIPOPROTEIN CHOLESTEROL; CHRONIC KIDNEY-DISEASE; MANAGING DYSLIPIDEMIA; NON-HDL; HEMODIALYSIS; ABNORMALITIES; POPULATION; GUIDELINES;
D O I
10.1371/journal.pone.0167258
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background With lipid level being a major contributing factor for cardiovascular health, the high cardiovascular mortality among dialysis patients has raised substantial concerns in regard to the optimal lipid level in these patient population. Objective To explore the optimal lipid level for the survival of dialysis patients. Methods The lipid profile was measured for each patient. All participants were followed throughout the course of the study. Cox proportional hazards analysis was performed to analyze the prognostic value of lipid level on the survival of these patients. Results In our study that included 311 stable maintenance dialysis patients, 54.98% of the participants had LDL-C level >= 100 mg/dl and 82.91% of the patients with triglycerides >= 200 mg/dl had non-HDL level >= 130 mg/dl. During the follow-up period of 48.0 (18.0, 55.5) months, 149 (47.91%) participants died. Among those who died, 59 patients died of cardiovascular disease (CVD) and 33 patients died of ischemic CVD (12.0, 4.7, and 2.7 events per 100 patient-years, respectively). Patients with LDL-C 100-130 mg/dl or non-HDL 130-160 mg/dl had a lower all-cause mortality rate than those who did not meet these criteria. After adjusting for the traditional and ESRD-related risk factors, non-HDL was found to be the independent risk factor for the all-cause mortality. Compared to those patients with non-HDL 130-160 mg/dl, patients with non-HDL < 100 mg/dl, 100-130 mg/dl, 160-190 mg/dl, or >= 190 mg/dl all had higher all-cause mortality: HR (95% CI) 3.207 (1.801, 5.713), 2.493 (1.485, 4.184), 2.476 (1.423, 4.307), and 1.917 (1.099, 3.345), respectively. There were no differences in nutrition, comorbidity, and inflammation indices among the patients with different non-HDL groups. However, patients with non-HDL of 130-160 mg/dl had the lowest corrected calcium and calcium phosphate product values as compared with other non-HDL groups. Conclusion Our study demonstrated that non-HDL 130-160 mg/dl might be the most appropriate lipid level in our dialysis patients. Our follow-up data also showed that patients with higher lipid level had poorer prognosis, just as in the general population.
引用
收藏
页数:14
相关论文
共 31 条
[1]   The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial [J].
Baigent, Colin ;
Landray, Martin J. ;
Reith, Christina ;
Emberson, Jonathan ;
Wheeler, David C. ;
Tomson, Charles ;
Wanner, Christoph ;
Krane, Vera ;
Cass, Alan ;
Craig, Jonathan ;
Neal, Bruce ;
Jiang, Lixin ;
Hooi, Lai Seong ;
Levin, Adeera ;
Agodoa, Lawrence ;
Gaziano, Mike ;
Kasiske, Bertram ;
Walker, Robert ;
Massy, Ziad A. ;
Feldt-Rasmussen, Bo ;
Krairittichai, Udom ;
Ophascharoensuk, Vuddidhej ;
Fellstrom, Bengt ;
Holdaas, Hallvard ;
Tesar, Vladimir ;
Wiecek, Andrzej ;
Grobbee, Diederick ;
de Zeeuw, Dick ;
Gronhagen-Riska, Carola ;
Dasgupta, Tanaji ;
Lewis, David ;
Herrington, William ;
Mafham, Marion ;
Majoni, William ;
Wallendszus, Karl ;
Grimm, Richard ;
Pedersen, Terje ;
Tobert, Jonathan ;
Armitage, Jane ;
Baxter, Alex ;
Bray, Christopher ;
Chen, Yiping ;
Chen, Zhengming ;
Hill, Michael ;
Knott, Carol ;
Parish, Sarah ;
Simpson, David ;
Sleight, Peter ;
Young, Alan ;
Collins, Rory .
LANCET, 2011, 377 (9784) :2181-2192
[2]   K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients [J].
Bolton, K ;
Beddhu, S ;
Campese, VM ;
Chavers, BM ;
Cheung, AK ;
Churchill, DN ;
Goldstein-Fuchs, J ;
Herzog, CA ;
Henrich, W ;
King, K ;
Kronenberg, F ;
Miholics, BS ;
Painter, PL ;
Parekh, R ;
Roberts, MS ;
Stehman-Breen, C ;
Stenvinkel, P ;
Wali, R ;
Weiss, MF .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (04) :S7-S153
[3]   Prediction of Mortality in Patients Undergoing Maintenance Hemodialysis by Charlson Comorbidity Index Using ICD-10 Database [J].
Chae, Je-Wook ;
Song, Chang Seok ;
Kim, Hyang ;
Lee, Kyu-Beck ;
Seo, Byeong-Sung ;
Kim, Dong-Il .
NEPHRON CLINICAL PRACTICE, 2011, 117 (04) :C379-C384
[4]   Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials [J].
Chan, Doris T. ;
Irish, Ashley B. ;
Dogra, Gursharan K. ;
Watts, Gerald F. .
ATHEROSCLEROSIS, 2008, 196 (02) :823-834
[5]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[6]   Hyperlipidemia and Long-Term Outcomes in Nondiabetic Chronic Kidney Disease [J].
Chawla, Varun ;
Greene, Tom ;
Beck, Gerald J. ;
Kusek, John W. ;
Collins, Allan J. ;
Sarnak, Mark J. ;
Menon, Vandana .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (09) :1582-1587
[7]   Excerpts from the United States Renal Data System 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States - Preface [J].
Collins, AJ ;
Kasiske, B ;
Herzog, C ;
Chen, SC ;
Everson, S ;
Constantini, E ;
Grimm, R ;
McBean, M ;
Xue, J ;
Chavers, B ;
Matas, A ;
Manning, W ;
Louis, T ;
Ma, J ;
Pan, W ;
Liu, JN ;
Li, SY ;
Roberts, T ;
Dalleska, F ;
Snyder, J ;
Ebben, J ;
Frazier, E ;
Sheets, D ;
Johnson, R ;
Li, SL ;
Dunning, S ;
Berrini, D ;
Guo, HF ;
Palzer, M ;
Solid, C ;
Arko, C ;
Daniels, F ;
Wang, XY ;
Gilbertson, D ;
St Peter, W ;
Frederick, P ;
Eggers, P ;
Agodoa, L .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) :V-IX
[8]   Serum non-high-density lipoprotein cholesterol (non-HDL-C) levels and cardiovascular mortality in chronic hemodialysis patients [J].
Echida, Yoshihisa ;
Ogawa, Tetsuya ;
Otsuka, Kuniaki ;
Ando, Yoshitaka ;
Nitta, Kosaku .
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2012, 16 (05) :767-772
[9]   Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis [J].
Fellstroem, Bengt C. ;
Jardine, Alan G. ;
Schmieder, Roland E. ;
Holdaas, Hallvard ;
Bannister, Kym ;
Beutler, Jaap ;
Chae, Dong-Wan ;
Chevaile, Alejandro ;
Cobbe, Stuart M. ;
Groenhagen-Riska, Carola ;
De Lima, Jose J. ;
Lins, Robert ;
Mayer, Gert ;
McMahon, Alan W. ;
Parving, Hans-Henrik ;
Remuzzi, Giuseppe ;
Samuelsson, Ola ;
Sonkodi, Sandor ;
Sueleymanlar, Gultekin ;
Tsakiris, Dimitrios ;
Tesar, Vladimir ;
Todorov, Vasil ;
Wiecek, Andrzej ;
Wuethrich, Rudolf P. ;
Gottlow, Mattis ;
Johnsson, Eva ;
Zannad, Faiez .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (14) :1395-1407
[10]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421